Ieq Capital LLC Invests $10.07 Million in Edwards Lifesciences Corporation $EW

Ieq Capital LLC purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 111,370 shares of the medical research company’s stock, valued at approximately $10,075,000.

A number of other large investors also recently bought and sold shares of EW. BlackRock Inc. bought a new stake in Edwards Lifesciences during the second quarter worth about $5,318,092,000. Bank of New York Mellon Corp bought a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $1,274,082,000. Norges Bank bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $803,686,000. Deutsche Bank AG bought a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $516,552,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after purchasing an additional 4,108,270 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 0.1%

Shares of Edwards Lifesciences stock opened at $89.89 on Friday. The company has a 50-day simple moving average of $89.21 and a two-hundred day simple moving average of $84.67. The stock has a market capitalization of $51.76 billion, a PE ratio of 51.66, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. UBS Group assumed coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They set a “buy” rating and a $110.00 price objective for the company. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $87.00 to $101.00 in a research note on Friday, July 24th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Finally, Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.